• news and publications | Enterprise Therapeutics | Treatment of respiratory diseases

PUBLICATIONS, NEWS & EVENTS

The discovery of potentiators of the calcium activated chloride channel, TMEM16A, oral communication at the Cystic Fibrosis Foundation Research Conference, Stevenson, USA, June 2017

June 1, 2017/by admin

Enterprise Therapeutics receives funding from Cystic Fibrosis Trust

Award will support research into the use of bronchosphere technology…
April 5, 2017/by admin

The discovery of novel TMEM16A potentiator compounds, presented at the Gordon research Conference, “Mucus & Mucociliary interactions”, Galveston, USA, February 2017

It is widely accepted that the composition of mucus in the CF…
February 1, 2017/by admin

Enterprise Therapeutics Announces £4 million ($5 million USD) Fundraising

Brighton, UK – 10th November, 2016: Enterprise Therapeutics…
November 10, 2016/by admin

Enterprise Therapeutics appoints Dr John Ford as CEO

Brighton, UK – October 17, 2016 - Enterprise Therapeutics Ltd,…
October 17, 2016/by admin

Flagellin-induces a hypersecretory phenotype in primary human bronchial epithelial cells, presented at North America Cystic Fibrosis Conference, Orlando, October 2016

The TLR5-agonist flagellin (FLG) is the key protein component…
October 1, 2016/by admin

Pharmacological characterisation of TMEM16A regulators, presented at The 13th European Cystic Fibrosis Basic Science Conference, Pisa, Italy, March 2016

TMEM16A was recently identified as a calcium-activated chloride…
March 2, 2016/by admin

Flagellin-induces a hypersecretory phenotype in primary human bronchial epithelial cells, presented at The 13th European Cystic Fibrosis Basic Science Conference, Pisa, Italy, March 2016

A screen of microbial-derived products using a 3D model of the…
March 1, 2016/by admin

New drug discovery company announces additional funding to tackle chronic respiratory disease

Brighton, Sussex, May 20th 2015 - ENTERPRISE THERAPEUTICS Ltd,…
May 20, 2015/by admin

World class drug discovery team launches new company to tackle chronic respiratory disease

Brighton, Sussex, February 12th 2015 - ENTERPRISE THERAPEUTICS…
February 12, 2015/by admin

Enterprise is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity – the company plans to initiate clinical trials in 2019.

Scientific Strategy

Enterprise is developing muco-regulatory drugs that are expected to help respiratory patients by improving their ability to breath and reduce the number of lung infections they experience leading to a longer and more healthy life.

Learn more

Pipeline

Enterprise has developed a pipeline of novel low molecular weight compounds with first in class potential – our most advanced compounds, which target ion channels in the airway epithelium are expected to enter human trials in late 2019.

Learn more